4. Savanna Starkey on behalf of The Estate of R. S., Deceased, Brandenburg, Kentucky, Court of Federal Claims No: 21–1646V
5. Joseph Delory, West Des Moines, Iowa, Court of Federal Claims No: 21–1648V
6. David Vazquez-Gonzalez, San Juan, Puerto Rico, Court of Federal Claims No: 21–1649V
7. Emyli Ferguson and Jeremy Ferguson on behalf of J. F., Glendale, Arizona, Court of Federal Claims No: 21–1650V
8. Jeffrey Sears and Brittney Sears on behalf of G. S., Roseville, New York, Court of Federal Claims No: 21–1651V
9. Jennifer L. Portock, Virginia Beach, Virginia, Court of Federal Claims No: 21–1653V
10. Weldon Wilson, Scottsdale, Arizona, Court of Federal Claims No: 21–1655V
11. Barbie Willett, Tyler, Texas, Court of Federal Claims No: 21–1656V
12. Deborah Beckwith, Louisville, Kentucky, Court of Federal Claims No: 21–1660V
13. Anthony Flores, Lovington, New Mexico, Court of Federal Claims No: 21–1661V
14. Louis Post, Poughkeepsie, New York, Court of Federal Claims No: 21–1662V
15. Chris Van Hulse, Jr., Phoenix, Arizona, Court of Federal Claims No: 21–1663V
16. Michelle Azzopardi, Dearborn, Michigan, Court of Federal Claims No: 21–1668V
17. Deborah Loring, Keene, New Hampshire, Court of Federal Claims No: 21–1670V
18. John Mohnal, Philadelphia, Pennsylvania, Court of Federal Claims No: 21–1671V
19. Steven Brooks, Oshkosh, Wisconsin, Court of Federal Claims No: 21–1672V
20. Sheila Cullen, Washington, District of Columbia, Court of Federal Claims No: 21–1673V
21. Melanie Worsley, Topeka, Kansas, Court of Federal Claims No: 21–1674V
22. Elizabeth Sears, Lawrenceville, New Jersey, Court of Federal Claims No: 21–1677V
23. Amy Gray, Boise, Idaho, Court of Federal Claims No: 21–1678V
24. Darlene E. Milne, Bellevue, Washington, Court of Federal Claims No: 21–1679V
25. Krista Elvin O'Brien and Robert O'Brien on behalf of M. O., Phoenix, Arizona, Court of Federal Claims No: 21–1680V
26. Alyssa Huber, Columbia, Tennessee, Court of Federal Claims No: 21–1681V
27. Ileana Matta on behalf of I. R., Boston, Massachusetts, Court of Federal Claims No: 21–1682V
28. Cori Rivas, Peoria, Illinois, Court of Federal Claims No: 21–1683V
29. Chelsea Pomponio, Lancaster, Pennsylvania, Court of Federal Claims No: 21–1687V
30. Keith Tillman, Salt Lake City, Utah, Court of Federal Claims No: 21–1688V
31. Kyle Pappas, Indianapolis, Indiana, Court of Federal Claims No: 21–1690V
32. Gregory Petraco, Port Jefferson Station, New York, Court of Federal Claims No: 21–1691V
33. Karrolee Tomchak, Santa Monica, California, Court of Federal Claims No: 21–1696V
34. Robert M. Claypool, Lancaster, Ohio, Court of Federal Claims No: 21–1697V
35. E. R. Hightower-Newell on behalf of R. B. Newell, North Las Vegas, Nevada, Court of Federal Claims No: 21–1698V
36. Ryan Sughrue, West Windsor, New Jersey, Court of Federal Claims No: 21–1699V
37. Arturo Vasquez, II, Phoenix, Arizona, Court of Federal Claims No: 21–1700V
38. Michelle Johnson, Springdale, Ohio, Court of Federal Claims No: 21–1707V
39. Rhonda Bryan, Tomball, Texas, Court of Federal Claims No: 21–1708V
40. Pamela Lewis-Nunez, Redondo Beach, California, Court of Federal Claims No: 21–1709V
41. Nancy Olivo, Glendale, New York, Court of Federal Claims No: 21–1710V
42. Christopher Hudson, Rockledge, Florida, Court of Federal Claims No: 21–1711V
43. Melissa B. Shine, Morehead City, North Carolina, Court of Federal Claims No: 21–1717V
44. Richard J. Tumas, Charlotte, North Carolina, Court of Federal Claims No: 21–1718V
45. Yvette Moyler, Columbus, Ohio, Court of Federal Claims No: 21–1720V
46. Michael Ritchey and Monica Ritchey on behalf of G. R., Little Rock, Arkansas, Court of Federal Claims No: 21–1724V
47. Nadine Robbins, Hyde Park, New York, Court of Federal Claims No: 21–1726V
48. Rivka Iliovits and Mordechie Iliovits on behalf of L. I., Staten Island, New York, Court of Federal Claims No: 21–1727V
49. Stephanie Felix and Ashton Felix on behalf of E. A. F., Bonita, California, Court of Federal Claims No: 21–1728V
50. Jill Shanti Zinzi, Phoenix, Arizona, Court of Federal Claims No: 21–1729V
51. Rebekah Schaffer, Cheyenne, Wyoming, Court of Federal Claims No: 21–1731V
52. Lori Wilson on behalf of A. W., Phoenix, Arizona, Court of Federal Claims No: 21–1732V
53. Katherine Miller, Huntingtown, Maryland, Court of Federal Claims No: 21–1733V
54. Paige Graves on behalf of D. G., Bartonville, Texas, Court of Federal Claims No: 21–1734V
55. Paloma Flood, Oviedo, Florida, Court of Federal Claims No: 21–1738V
56. David D. Bronson, Rancho Santa Margarita, California, Court of Federal Claims No: 21–1741V
57. Robert Zampitella, Philadelphia, Pennsylvania, Court of Federal Claims No: 21–1743V
58. Aina Rizvi, Phoenix, Arizona, Court of Federal Claims No: 21–1744V
59. Claire Panella, Stuart, Florida, Court of Federal Claims No: 21–1748V
60. Deborah Hammond, East Norriton, Pennsylvania, Court of Federal Claims No: 21–1749V
61. Monique Coombes, Boise, Idaho, Court of Federal Claims No: 21–1750V
62. Dr. Michelle Perez, Stratford, Connecticut, Court of Federal Claims No: 21–1753V
63. Matthew Rivera, Pembroke Pines, Florida, Court of Federal Claims No: 21–1754V
64. Wendy Miller, Torrington, Connecticut, Court of Federal Claims No: 21–1756V
65. Nancy Sorge, Monroe, Connecticut, Court of Federal Claims No: 21–1759V
66. Monica Godoy, Seattle, Washington, Court of Federal Claims No: 21–1760V
67. Christy Bright, Houston, Texas, Court of Federal Claims No: 21–1761V
68. Barton Bond, Fayetteville, Georgia, Court of Federal Claims No: 21–1764V
69. Mary Jo Drcar, Mentor, Ohio, Court of Federal Claims No: 21–1766V
70. Justin Boggs, Wellesley Hills, Massachusetts, Court of Federal Claims No: 21–1767V
71. Robert Schenck, Spring Hill, Florida, Court of Federal Claims No: 21–1768V
72. Amarah Elzabad, Boston, Massachusetts, Court of Federal Claims No: 21–1771V
73. Silvia Bavli, Phoenix, Arizona, Court of Federal Claims No: 21–1772V
74. Felicia R. Williams, St. Louis, Missouri, Court of Federal Claims No: 21–1774V
75. Fazal Siddiqui, Chicago, Illinois, Court of Federal Claims No: 21–1776V
76. Tommy E. Martin, Mt. Holly, North Carolina, Court of Federal Claims No: 21–1777V
77. Lynn Peterson, Waukesha, Wisconsin, Court of Federal Claims No: 21–1778V
78. Bailey Thomas on behalf of A. B., Englewood, New Jersey, Court of Federal Claims No: 21–1780V
79. Anita Richardson, Pensacola, Florida, Court of Federal Claims No: 21–1781V
80. Leah Gonzalez-Guzman, White Plains, New York, Court of Federal Claims No: 21–1782V

[FR Doc. 2021–20233 Filed 9–17–21; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Findings of research misconduct have been made against Ya Wang, M.D., Ph.D. (Respondent), retired Professor and Director, Division of Experimental Radiation Oncology, Department of Radiation Oncology, Winship Cancer Institute, Emory University (EU). Respondent engaged in research misconduct in research supported by U.S. Public Health Service (PHS) funds, specifically National Cancer Institute (NCI), National Institutes of Health (NIH), grants P30 CA138292 and R01 CA186129 and National Institute of General Medical Sciences (NIGMS), NIH, grant R01 GM080771. The administrative actions, including debarment for a period of four (4) years, were implemented beginning on August 4, 2021, and are detailed below.

FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr. P.H., Acting Director, Office of Research Integrity,

1101 Wootton Parkway, Suite 240, Rockville, MD 20852, (240) 453–8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Ya Wang, M.D., Ph.D., Emory University: Based on the report of an inquiry conducted by EU and analysis conducted by ORI in its oversight review, ORI found that Dr. Ya Wang, retired Professor and Director, Division of Experimental Radiation Oncology, Department of Radiation Oncology, Winship Cancer Institute, EU, engaged in research misconduct in research supported by PHS funds, specifically NCI, NIH, grants P30 CA138292 and R01 CA186129 and NIGMS, NIH, grant R01 GM080771.

Respondent neither admits nor denies ORI's findings of research misconduct. The settlement is not an admission of liability on the part of the Respondent. The parties entered into a Voluntary Exclusion Agreement to conclude this matter without further expenditure of time, finances, or other resources.

ORI found that Respondent engaged in research misconduct by knowingly, intentionally, and/or recklessly falsifying data that were included in the following one (1) PHS grant application and six (6) published papers:

• R21 HL154577–01, ''GPRC5A Inhibits Error-Prone Repair to Maintain Lung Genomic Integrity,'' submitted to the National Heart, Lung, and Blood Institute (NHLBI), NIH, on December 13, 2019.

• miR–21-Mediated Radioresistance Occurs via Promoting Repair of DNA Double Strand Breaks. *J Biol Chem.* 2017 Feb 24;292(8):3531–40; doi: 10.1074/jbc.M116.772392 (hereafter referred to as ''*J Biol Chem.* 2017''). Retraction in: *J Biol Chem.* 2020 May 1;295(18):6250; doi: 10.1074/jbc.W120.013725.

• Distinct Roles of Ape1 Protein, an Enzyme Involved in DNA Repair, in High or Low Linear Energy Transfer Ionizing Radiation-Induced Cell Killing. *J Biol Chem.* 2014 Oct 31; 289(44):30635–44; doi: 10.1074/jbc.M114.604959 (hereafter referred to as ''*J Biol Chem.* 2014''). Retraction in: *J Biol Chem.* 2020 May 1;295(18):6249; doi: 10.1074/jbc.W120.013724.

• OCT4 as a Target of miR–34a Stimulates p63 but Inhibits p53 to Promote Human Cell Transformation. *Cell Death Dis.* 2014 Jan 23;5(1):e1024; doi: 10.1038/cddis.2013.563 (hereafter referred to as ''*Cell Death Dis.* 2014'').

• MicroRNA–21 Modulates the Levels of Reactive Oxygen Species by Targeting SOD3 and TNFα. *Cancer Res.* 2012 Sep 15;72(18):4707–13; doi: 10.1158/0008–5472.CAN–12–0639 (hereafter referred to as ''*Cancer Res.* 2012a'').

• RNAi-Mediated Targeting of Noncoding and Coding Sequences in DNA Repair Gene Messages Efficiently Radiosensitizes Human Tumor Cells. *Cancer Res.* 2012 Mar 1; 72(5):1221–8; doi: 10.1158/0008–5472.CAN–11–2785 (hereafter referred to as ''*Cancer Res.* 2012b'').

• Over-Expression of miR–100 is Responsible for the Low-Expression of ATM in the Human Glioma Cell Line: M059J. *DNA Repair (Amst).* 2010 Nov 10;9(11):1170–5; doi: 10.1016/j.dnarep.2010.08.007 (hereafter referred to as ''*DNA Repair* 2010'').

ORI found that respondent knowingly, intentionally, and/or recklessly falsified protein immunoblot data by reusing and relabeling the same images to represent different experimental conditions in mammalian tissue culture models of DNA damage and repair in eighteen (18) figure panels in eleven (11) figures in one (1) grant application and six (6) published papers.

Specifically:

• Western blot images for total protein expression in distinct transgenic mouse cell lines were falsified by reusing immunoblot bands and relabeling them to represent different experiments in eleven (11) figure panels in two (2) papers, including:

—Figure 3D in *J Biol Chem.* 2017, representing β-actin expression (left side panel) in wildtype (WT), microRNA–21 (miR–21) knock-in, and miR–21$^{-/-}$ mouse embryonic fibroblast (MEF) cells exposed to irradiation

—Figure 4C in *J Biol Chem.* 2017, representing DNA–PKcs expression in miR–21 knock-in MEF cells exposed to irradiation

—Figure 5A in *J Biol Chem.* 2017, representing CDC25A and β-actin expression in WT, GSK3B$^{-/-}$, and Cyclin D1$^{-/-}$ MEF cells transfected with control or gene-specific silencing RNA (siRNA)

—Figure 1 in *J Biol Chem.* 2014, representing β-actin expression in Ku80$^{-/-}$ (Figure 1A) and Ogg1$^{-/-}$ (Figure 1C) MEF cells transfected with expression or control vectors

—Figure 3 in *J Biol Chem.* 2014, representing H2A expression in WT MEF (Figure 3A), Ku80$^{-/-}$ MEF (Figure 3B), Ogg1$^{-/-}$ MEF (Figure 3C), and Ogg1^{+} (rescue) MEF (Figure 3D) cells transfected with expression or control vectors and in the absence or presence of radiation exposure

—Figure 3D in *J Biol Chem.* 2014, representing Mre11 (left panel) expression in Ogg1^{+} (rescue) MEF cells transfected with expression or control vectors in the absence or presence of radiation exposure

—Figure 4B in *J Biol Chem.* 2014, representing Mre11 expression in Ogg1$^{-/-}$ MEF cells with control or Ape1 expression vector in the presence of low or high linear energy transfer (LET) irradiation

—Figure 5C in *J Biol Chem.* 2014, representing Ape1 and β-actin expression in WT MEF cells with or without gene depletion and transfected with control or various Ape1 expression vectors

• western blot images for total protein expression in human cell lines subject to gene depletion and/or overexpression were falsified by reusing immunoblot bands and relabeling them to represent different experiments in seven (7) figure panels in five (5) papers and one (1) grant application, including:

—Figure 4A in NIH grant application R21 HL154577–01, representing GPRC5A levels in different patient-derived cell lines with gene suppression or depletion

—Figure 4D in *J Biol Chem.* 2017, representing total DNA–PKcs, phosphorylated DNA–PKcs, CDC25A, and GSK3B levels in human embryonic kidney cells transfected with controls or various expression vectors and/or miR–21 mimics

—Figure 5C in *J Biol Chem.* 2017, representing CDC25A, GSK3B, Cyclin D1, and β-actin expression in human embryonic kidney cells with or without gene depletion and transfected with controls or miR–21 mimics

—Figure 5B in *Cell Death Dis.* 2014, representing p53 and p63 levels in human lung epithelial cells with or without gene depletion

—Figure 3A in *Cancer Res.* 2012a, representing TNFα levels in control and miR–21 overexpressing human lung epithelial cells at different time points following irradiation

—Figure 5A in *Cancer Res.* 2012b, representing XRCC4 levels in both human lung and brain epithelial cells with gene depletion at multiple time points and treated with or without an artificial microRNA

—Figure 3A in *DNA Repair* 2010, representing ATM and Ku70 levels in human glioblastoma-derived cells with or without gene depletion

• western blot images for proteins from chromatin DNA complexes in mouse cell lines transfected with control or expression vectors and in the absence or presence of irradiation were falsified by reusing immunoblot bands

and relabeling them to represent different experiments in three (3) figure panels in one (1) paper, including:

—Figure 3 in *J Biol Chem.* 2014, representing chromatin-bound γ-H2AX levels in WT MEF (Figure 3A), $Ogg1^{-/-}$ MEF (Figure 3C), and $Ogg1^{+}$ (rescue) MEF (Figure 3D) cells transfected with a control or expression vector and in the absence or presence of irradiation

Dr. Wang entered into a Voluntary Exclusion Agreement (Agreement) and voluntarily agreed to the following:

(1) Respondent agreed to exclude herself voluntarily for a period of four (4) years beginning on August 4, 2021, from any contracting or subcontracting with any agency of the United States Government and from eligibility for or involvement in nonprocurement programs of the United States Government referred to as ''covered transactions'' pursuant to HHS' Implementation (2 CFR part 376) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the ''Debarment Regulations'').

(2) Respondent agreed to exclude herself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of four (4) years, beginning on August 4, 2021.

(3) As a condition of the Agreement, Respondent will request that the following papers be corrected or retracted in accordance with 42 CFR 93.407(a)(1) and § 93.411(b):

- *Cell Death Dis.* 2014 Jan;5(1):e1024
- *Cancer Res.* 2012 Sep 15;72(18):4707–13
- *Cancer Res.* 2012 Mar 1;72(5):1221–8
- *DNA Repair (Amst).* 2010 Nov 10;9(11):1170–5

Respondent will copy ORI and the Research Integrity Officer at EU on the correspondence.

Dated: September 15, 2021.

Wanda K. Jones,

Acting Director, Office of Research Integrity, Office of the Assistant Secretary for Health.

[FR Doc. 2021–20268 Filed 9–17–21; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Document Identifier: OS–0990–xxxx]

Agency Father Generic Information Collection Request. 60-Day Public Comment Request

AGENCY: Office of the Secretary, Health and Human Services (HHS).

ACTION: 60-Day notice of public information collections.

SUMMARY: In compliance with the requirement of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, is publishing the following summary of a proposed collection for public comment.

DATES: Comments on the ICR must be received on or before November 19, 2021.

ADDRESSES: Submit your comments to *Sherrette.Funn@hhs.gov* or by calling (202) 795–7714.

FOR FURTHER INFORMATION CONTACT: When submitting comments or requesting information, please include the document identifier 0990-New-60D, and project title for reference, to Sherrette Funn, the Reports Clearance Officer, *Sherrette.funn@hhs.gov,* or call 202–795–7714.

SUPPLEMENTARY INFORMATION: Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Title of the Collection: Evaluation of the National Hypertension Control Initiative (NHCI).

Type of Collection: NEW Generic.

OMB No. 0990—OS/Office of Minority Health (OMH)

Abstract: As part of the federal response to COVID–19, the U.S. Department of Health and Human Services (HHS) has funded a new initiative involving two cooperative agreements with the American Heart Association (AHA) to improve COVID–19-related health outcomes by addressing hypertension (high blood pressure) among racial and ethnic minority populations.

The $32 million project from the HHS Office of Minority Health (OMH) and the Health Resources and Services Administration (HRSA) Bureau of Primary Health Care will support the implementation of the National Hypertension Control Initiative (NHCI), a national initiative to improve blood pressure control among the most at-risk populations, including racial and ethnic minorities.

The NHCI will support 350 participating HRSA-funded health centers by providing patient and provider education and training for effective hypertension control as well as integration of remote blood pressure monitoring technology into the treatment of hypertension for patients served by participating health centers. The project will also utilize the American Heart Association's targeted media campaigns and existing partnerships with community-based organizations (CBOs) to help reach Black, Latino, and other impacted communities with (i) culturally and linguistically appropriate messages, (ii) access to blood pressure screenings, and (iii) connection to health centers to encourage proper treatment and management of hypertension of screened individuals. This initiative serves to increase the number of adult patients with controlled hypertension and reduce the potential risk of COVID-related health outcomes.

AHA aims to conduct an evaluation to assess the feasibility of the implementation of each of the three NHCI strategies. The findings of this evaluation will inform the improvement and tailoring of AHA's communication approaches about the importance of and techniques for improving blood pressure control, including the benefits of accurately measuring, rapidly acting, and having a patient-focused approach to blood pressure control.

Methodology: The evaluation of the NHCI project will use a mixed methods design, integrating both quantitative and qualitative data collection and analyses. Three main goals of data collection will be to: (1) Track and monitor systems change implementation process information from Community Health Centers (CHCs) on a quarterly basis, (2) assess the capacity of NHCI partners to implement the NHCI project, their needs, the strengths and weaknesses of the systems change approach, and the feasibility of the implementation of the NHCI in their organizations and communities, and (3) assess the reach and success of NHCI project strategies implemented by partners.